Efficacy and safety of current drug therapies for invasive aspergillosis

Pharmacology

Volumn 88, Issue 3-4, 2011, Pages 213-224

  Traunmüller, Friederike ^a   Popovic, Martin ^a,b   Konz, Karl Heinz ^d   Smolle Jüttner, Freyja Maria ^c   Joukhadar, Christian ^a,e,f  

^a J & P Medical Research Ltd   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

^d KLINIKEN MARIA HILF GMBH   (Germany)

^e Beth Israel Deaconess Medical Center   (Israel)

^f HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Echinocandins; Haemopoietic stem cell transplantation; Invasive fungal infections; Liposomal amphotericin B; Molds; Nephrotoxicity; Triazoles

Indexed keywords

ALBACONAZOLE; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CASPOFUNGIN; ISAVUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; RAVUCONAZOLE; VORICONAZOLE;

ASPERGILLUS; BLURRED VISION; CARDIOTOXICITY; CHEILITIS; COLOR VISION DEFECT; COMBINATION CHEMOTHERAPY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULARY; DRUG INDUCED HEADACHE; DRUG PENETRATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHEMA; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HUMAN; HYPOGLYCEMIA; INVASIVE ASPERGILLOSIS; LOW DRUG DOSE; MELANOMA; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; PHOTOPHOBIA; PHOTOSENSITIVITY DISORDER; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; REMISSION; REVIEW; RISK FACTOR; SIDE EFFECT; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; DRUG THERAPY, COMBINATION; ECHINOCANDINS; HUMANS; TREATMENT OUTCOME; TRIAZOLES;

EID: 80053462372     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000331860     Document Type: Review

References (93)

1. Neofytos D, Horn D, Anaissie E, Steinbach W, Olyaei A, Fishman J, Pfaller M, Chang C, Webster K, Marr K: Epidemiology and outcome of invasive fungal infection in adult haematopoietic stem cell transplant recipients: analysis of multicenter prospective antifungal therapy (PATH) Alliance Registry. Clin Infect Dis 2009; 48: 265-273.
2. Lortholary O, Charlemagne A, Bastides F, Chevalier P, Datry A, Gonzalves M, Michel G, Tilleul P, Veber B, Herbrecht R: A multicentre pharmacoepidemiological study of therapeutic practices in invasive fungal infections in France during 1998-1999. J Antimicrob Chemother 2004; 54: 456-464. (Pubitemid 39177470)
3. Krishnan S, Manavathu EK, Chandrasekar PH: Aspergillus flavus: an emerging non-fumigatus Aspergillus species of significance. Mycoses 2009; 52: 206-222.
4. Bonnett CR, Cornish EJ, Harmsen AG, Burritt JB: Early neutrophil recruitment and aggregation in the murine lung inhibit germination of Aspergillus fumigatus conidia. Infect Immun 2006; 74: 6528-6539. (Pubitemid 44913127)
5. Yousem SA: The histological spectrum of chronic necrotizing forms of pulmonary aspergillosis. Hum Pathol 1997; 28: 650-656. (Pubitemid 27258417)
6. Almutairi BM, Nguyen TB, Jansen GH, Asseri AH: Invasive aspergillosis of the brain: radiologic-pathologic correlation. Radiographics 2009; 29: 375-379.
7. Gorelik O, Cohen N, Shpirer I, Almoznino-Sarafian D, Alon I, Koopfer M, Yona R, Modai D: Fatal haemoptysis induced by invasive pulmonary aspergillosis in patients with acute leukaemia during bone marrow and clinical remission: report of two cases and review of the literature. J Infect 2000; 41: 277-282. (Pubitemid 32051052)
8. Gallien S, Fournier S, Porcher R, Bottero J, Ribaud P, Sulahian A, Socié G, Molina JM: Therapeutic outcome and prognostic factors of invasive aspergillosis in an infectious disease department: a review of 34 cases. Infection 2008; 36: 533-538.
9. Baddley JW, Marr KA, David RA, Walsh TJ, Kauffman CA, Kontoyiannis DP, Ito JI, Arunmozhi Balajee S, Pappas PG, Moser SA: Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network. J Clin Micobiol 2009; 47: 3271-3275.
10. Denning DW, Stevens DA: Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev Infect Dis 1990; 12: 1147-1201.
11. Cakir FB, Cakir E, Berrak SG, Uyan ZS, Canpolat C, Karakoc F, Dagli E: Invasive respiratory aspergillosis is a treatable disease with early diagnosis and aggressive therapy. Pediatr Hematol Oncol 2010; 27: 422-434.
12. Ali R, Ozkalemkas F, Ozcelik T, Ozkocaman V, Ozkan A, Bayram S, Ener B, Ursavas A, Oza G, Tunali A: Invasive pulmonary aspergillosis: role of early diagnosis and surgical treatment in patients with acute leukemia. Ann Clin Microbiol Antimicrob 2006; 27: 17.
13. Vehreschild JJ, Rüping MJ, Steinbach A, Cornely OA: Diagnosis and treatment of fungal infections in allogeneic stem cell and solid organ transplant recipients. Expert Opin Pharmacother 2010; 11: 95-113.
14. Khan MA, Dar AM, Kawoosa NU, Ahangar AG, Lone GN, Bashir G, Bhat MA, Singh S: Clinical profile and surgical outcome for pulmonary aspergilloma: nine year retrospective observational study in a tertiary care hospital. Int J Surg 2011; 9: 267-271.
15. Gallis HA, Drew RH, Pickard WW: Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990; 12: 308-329. (Pubitemid 20118658)
16. Denning DW: Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 1996; 23: 608-615. (Pubitemid 26304513)
17. Mouton JW, te Dorsthorst DT, Meis JF, Verweij PE: Dose-response relationships of three amphotericin B formulations in a non-neutropenic murine model of invasive aspergillosis. Med Mycol 2009; 47: 802-807.
18. Olson JA, Adler-Moore JP, Julie Schwartz J, Jensen GM, Proffitt RT: Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model. Antimicrob Agents Chemother 2006; 50: 2122-2131. (Pubitemid 43807534)
19. Leenders ACAP, Daenen S, Jansen RL, Hop WCJ, Lowenberg B, Wijermans PW, Cornelissen J, Herbrecht R, Van der Lelie H, Hogsteden HC, Verbrugh HA, De Marie S: Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropeniaassociated invasive fungal infections. Br J Haematol 1998; 103: 205-212. (Pubitemid 28470819)
20. Bowden R, Chandrasekar P, White MH, Xin X, Pietrelli L, Gurwith M, van Burik J, Laverdiere M, Safrin S, Wingard JR: A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2002; 35: 359-366. (Pubitemid 34852563)
21. Walsh TJ, Hiemez J, Seibel NL, Perfect JR, Horwith G, Lee L, Silber JL, Di Nubile MJ, Reboli A, Bow E, Lister J, Anaissie EJ: Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998; 26: 1383-1396. (Pubitemid 28270170)
22. Denning DW, Marinus A, Cohen J, Spence D, Herbecht R, Pagano L, Kibbler C, Kcmery V, Offner F, Cordonnier C, Jehn U, Ellis M, Collette L, Sylvester R, the EORTC Invasive Fungal Infections Cooperative Group. An EORTC multicenter prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. J Infect 1998; 37: 173-180. (Pubitemid 28482922)
23. Wingard JR: Efficacy of amphotericin B lipid complex injection (ABLC) in bone marrow transplant recipients with life-threatening systemic mycoses. Bone Marrow Transplant 1997; 19: 343-347. (Pubitemid 27096066)
24. Ringdén O, Marnier F, To Demar J, Rkof P, Tura S, Kuse E, Viviani MA, Gorin NC, Klastersky J, Fenaux P, Prentice HG, Ksionski G: Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrob Chemother 1991; 28(suppl B):73-82.
25. Ellis M, Spence D, de Pauw B, Meunier F, Marinus A, Collette L, Sylvester R, Meis J, Boogaerts M, Selleslag D, Krcmery V, von Sinner W, MacDonald P, Doyen C, Vandercam B: An EORTC international multicenter randomized trial (EORTC Number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin Infect Dis 1998; 27: 1406-1412. (Pubitemid 29242412)
26. Cornely OA, Maertens J, Bresnik M, Ebrahimi R, Ullmann AJ, Bouza E, Heussel CP, Lortholary O, Rieger C, Boehme A, Aoun M, Horst HA, Thiebaut A, Ruhnke M, Reichert D, Vianelli N, Krause SW, Olavarria E, Herbrecht R, AmBiLoad Trial Study Group: Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBi-Load Trial). Clin Infect Dis 2007; 44: 1289-1297. (Pubitemid 46717290)
27. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Green RE, Oestmann J, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw P, Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group: Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-415.
28. Denning DW, Ribaud P, Milpied N, Caillot D, Herbrecht R, Thiel E, Haas A, Ruhnke M, Lode H: Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34: 563-571. (Pubitemid 34165316)
29. Caillot D, Bassaris H, McGeer A, Arthur C, Prentice HG, Seifert W, De Beule K: Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. Clin Infect Dis 2001; 33:e83-e90.
30. Walsh TJ, Raad I, Patterson TF, Chandrasekar P, Donowitz GR, Graybill R, Greene RE, Hachem R, Hadley S, Herbrecht R, Langston A, Louie A, Ribaud P, Segal BH, Stevens DA, van Burik JH, White CS, Corcoran G, Gogate J, Krishna G, Pedicone L, Hardalo C, Perfect JR: Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007; 44: 2-12. (Pubitemid 44968977)
31. Viscoli C, Herbrecht R, Akan H, Baila L, Sonet A, Gallamini A, Giagounidis A, Marchetti O, Martino R, Meert L, Paesmans M, Ameye L, Shivaprakash M, Ullmann AJ, Maertens J, Infectious Disease Group of the EORTC: An EORTC phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients. J Antimicrob Chemother 2009; 64: 1274-1281.
32. Herbrecht R, Maertens J, Baila L, Aoun M, Heinz W, Martino R, Schwartz S, Ullmann AJ, Meert L, Paesmans M, Marchetti O, Akan H, Ameye L, Shivaprakash M, Viscoli C, Infectious Diseases Group of the EORTC: Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study. Bone Marrow Transplant 2010; 45: 1227-1233.
33. Sau K, Mambula SS, Latz E, et al: The antifungal drug amphotericin B promotes inflammatory cytokine release by a toll-like receptor-and CD14-dependent mechanism. J Biol Chem 2003; 278: 37561-37568. (Pubitemid 37175278)
34. Goodwin SD, Cleary JD, Walawander CA, Taylor JW, Grasela TH: Pretreatment regimens for adverse events related to infusion of amphotericin B. Clin Infect Dis 1995; 20: 755-761.
35. Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, Pappas P, Seibel NL, Greenberg RN, Dummer S, Schuster M, Holcenberg JS, National Institute of Allergy and Infectious Diseases Mycosis Study Group: Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999; 340: 764-771. (Pubitemid 29114295)
36. Googe JH, Walterspiel JN: Arrhythmia caused by amphotericin B in a neonate. Pediatr Infect Dis J 1988; 7: 73. (Pubitemid 18040776)
37. Danaher PJ, Cao MK, Anstead GM, Dolan MJ, De Witt CC: Reversible dilated cardiomyopathy related to amphotericin B therapy. J Antimicrob Chemother 2004; 53: 115-117. (Pubitemid 38072194)
38. Walker RW, Rosenblum MK: Amphotericin B-associated leukoencephalopathy. Neurology 1992; 42: 2005-2010.
39. Fanos V, Cataldi L: Amphotericin B-induced nephrotoxicity: a review. J Chemother 2000; 12: 463-470. (Pubitemid 32048160)
40. Anderson CM: Sodium chloride treatment of amphotericin B nephrotoxicity. West J Med 1995; 162: 313-317.
41. Kleinberg M: What is the current and future status of conventional amphotericin B? Int J Antimicrob Agents 2006; 27S:S12-S16.
42. Sutton DA, Sanche SE, Revankar SG, Fothergill AW, Rinaldi MG: In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole. J Clin Microbiol 1999; 37: 2343-2345. (Pubitemid 29277804)
43. Li-Wan-Po A, Girard T, Farndon P, Cooley C, Lithgow J: Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19 * 17. Br J Clin Pharmacol 2010; 69: 222-230.
44. Brüggemann RJM, Alffenaar JC, Blijlevens NMA, Billaud EM, Kosterink JGW, Verweij PE, Burger DM: Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis 2009; 48: 1441-1458.
45. Walsh TJ, Karlsson MO, Driscoll T, Arguedas AG, Adamson P, Saez-Llorens X, Vora AJ, Arrieta AC, Blumer J, Lutsar I, Milligan P, Wood N: Pharmacokinetics and safety of intravenous voriconazole in children after single-or multiple-dose administration. Antimicrob Agents Chemother 2004; 48: 2166-2172. (Pubitemid 38691615)
46. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O: Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46: 201-211. (Pubitemid 351269158)
47. Herbrecht R: Voriconazole: therapeutic review of a new azole antifungal. Expert Rev Anti-Infect Ther 2004; 2: 485-497. (Pubitemid 39162360)
48. Walsh TJ, Lutsar I, Driscoll T, Dupont B, Roden M, Gharahmani P, Hodges M, Groll AH, Perfect JR: Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 2002; 21: 240-248. (Pubitemid 34214142)
49. Abbassi S, Shenep JL, Hughes WT, Flynn PM: Aspergillosis in children with cancer: a 34-year experience. Clin Infect Dis 1999; 29: 1210-1219. (Pubitemid 30265641)
50. Shetty D, Giri N, Gonzalez CE, Pizzo PA, Walsh TJ: Invasive aspergillosis in human immunodeficiency virus-infected children. Pediatr Infect Dis J 1997; 16: 216-221. (Pubitemid 27078793)
51. Walmsley S, Devi S, King S, Schneider R, Richardson S, Ford-Jones L: Invasive Aspergillus infections in a pediatric hospital: a tenyear review. Pediatr Infect Dis J 1993; 12: 673-682. (Pubitemid 23231164)
52. Patterson TF, Boucher HW, Herbrecht R, Denning DW, Lortholary O, Ribaud P, Rubin RH, Wingard JR, De Pauw B, Schlamm HT, Troke P, Bennett JE, European Organization for Research and Treatment of Cancer (EORTC) Invasive Fungal Infections Group (IFIG) and the Pfizer Global Aspergillus Study Group: Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome. Clin Infect Dis 2005; 41: 1448-1452. (Pubitemid 41579987)
53. Smith J, Safdar N, Knasinski V, Simmons W, Bhavnani SM, Ambrose PG, Andes D: Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006; 50: 1570-1572.
54. Böhme A, Ruhnke M, Buchheidt D, Karthaus M, Einsele H, Guth S, Heussel G, Heussel C, Junghanss C, Kern WK, Kubin T, Maschmeyer G, Sezer O, Silling G, Südhoff T, Szelenyi H, Ullmann AJ: Treatment of fungal infections in hematology and oncology. Ann Hematol 2003; 82(suppl 2):S133-S140.
55. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, van Burik J, Wingard JR, Patterson TF: Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 327-360. (Pubitemid 351265310)
56. Boyd AE, Modi S, Howard SJ, Moore CB, Keevil BG, Denning DW: Adverse reactions to voriconazole. Clin Infect Dis 2004; 39: 1241-1244. (Pubitemid 40169325)
57. McCarthy KL, Playford EG, Looke DF, Whitby M: Severe photosensitivity causing multifocal squamous cell carcinomas secondary to prolonged voriconazole therapy. Clin Infect Dis 2007; 44:e55-e56.
58. Cowen EW, Nguyen JC, Miller DD, Mc-Shane D, Arron ST, Prose NS, Turner ML, Fox LP: Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole. J Am Acad Dermatol 2010; 62: 31-37.
59. Miller DD, Cowen EW, Nguyen JC, Mc-Calmont TH, Fox LP: Melanoma associated with long-term voriconazole therapy: a new manifestation of chronic photosensitivity. Arch Dermatol 2010; 146: 300-304.
60. Morice C, Acher A, Soufir N, Michel M, Comoz F, Leroy D, Verneuil L: Multifocal aggressive squamous cell carcinomas induced by prolonged voriconazole therapy: a case report. Case Report Med 2010; 2010: 351084.
61. Howard A, Hoffman J, Sheth A: Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis. Ann Pharmacother 2008; 42: 1859-1864.
62. Kadikoy H, Barkmeier A, Peck B, Carvounis PE: Persistent photopsia following course of oral voriconazole. J Ocul Pharmacol Ther 2010; 26: 387-388.
63. Barone JA, Moskovitz BL, Guarnieri J, Hassell AE, Colaizzi JL, Bierman RH, Jessen L: Enhanced bioavailability of itraconazole in hydroxypropyl-beta- cyclodextrin solution versus capsules in healthy volunteers. Antimicrob Agents Chemother 1998; 42: 1862-1865. (Pubitemid 28311595)
64. Caillot D: Intravenous itraconazole followed by oral itraconazole for the treatment of amphotericin-B-refractory invasive pulmonary aspergillosis. Acta Haematol 2003; 109: 111-118. (Pubitemid 36506370)
65. Denning DW, Lee JY, Hostetler JS, Pappas P, Kauffman CA, Dewsnup DH, Galgiani JN, Graybill JR, Sugar AM, Catanzaro A, Gallis H, Perfect JR, Dockery B, Dismukes WE, Stevens DA: NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med 1994; 97: 135-144. (Pubitemid 24250673)
66. Herbrecht R, Flückinger U, Gachot B, et al: Antifungal therapy in leukemia patients. 2009 update of the ECIL-1 and ECIL-2 guidelines. 3rd European Conference on Infections in Leukemia, September 25-26, 2009, Juan-Les-Pins, France. http://www. eortc.be/home/IDG/ECIL/ECIL3-Antifungal-therapy-Update-2009. pdf (accessed July 18, 2011).
67. Sánchez-Ortega I, Patiño B, Arnan M, Peralta T, Parody R, Gudiol C, Encuentra M, Fernández de Sevilla A, Duarte RF: Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole vs itraconazole in allogeneic blood and marrow transplantation. Bone Marrow Transplant 2011; 46: 733-739.
68. Pfaller MA, Diekema DJ, Ghannoum MA, Rex JH, Alexander BD, Andes D, Brown SD, Chaturvedi V, Espinel-Ingroff A, Fowler CL, Johnson EM, Knapp CC, Motyl MR, Ostrosky-Zeichner L, Sheehan DJ, Walsh TJ, Clinical and Laboratory Standards Institute Antifungal Testing Subcommittee: Wildtype MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methods. J Clin Microbiol 2009; 47: 3142-3146.
69. Groll AH, Walsh TJ: Antifungal efficacy and pharmacodynamics of posaconazole in experimental models of invasive fungal infections. Mycoses 2006; 49(suppl 1):7-16. (Pubitemid 44370096)
70. Lodge BA, Ashley ED, Steele MP, Perfect JR: Aspergillus fumigatus empyema, arthritis, and calcaneal osteomyelitis in a lung transplant patient successfully treated with posaconazole. J Clin Microbiol 2004; 42: 1376-1378. (Pubitemid 38332896)
71. Zoller E, Valente C, Baker K, Klepser ME: Development, clinical utility, and place in therapy of posaconazole for prevention and treatment of invasive fungal infections. Drug Des Dev Ther 2010; 4: 299-311.
72. Verweij PE, Snelders E, Kema GH, Mellado E, Melchers WJ: Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use? Lancet Infect Dis 2009; 9: 789-795.
73. Lockhart SR, Frade JP, Etienne KA, Pfaller MA, Diekema DJ, Balajee SA: Azole resistance in Aspergillus fumigatus isolates from the ARTEMIS global surveillance is primarily due to the TR/L98H mutation in the cyp51A gene. Antimicrob Agents Chemother 2011; 55: 4465-4468.
74. Van der Linden JW, Warris A, Verweij PE: Aspergillus species intrinsically resistant to antifungal agents. Med Mycol 2011; 49(suppl 1):S82-S89.
75. Douglas CM: Fungal beta(1,3)-D-glucan synthesis. Med Mycol 2001; 39(suppl 1):55-66.
76. Maertens J, Raad I, Petrikkos G, et al: Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39: 1563-1571. (Pubitemid 39578526)
77. Zaoutis TE, Jafri HS, Huang L, Locatelli F, Barzilai A, Ebell W, Steinbach WJ, Bradley J, Lieberman JM, Hsiao C, Seibel N, Laws H, Gamba M, Petrecz M, Taylor AF, Strohmaier KM, Chow JW, Kartsonis NA, Ngai AL: A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients. Pediatrics 2009; 123: 877-884.
78. Caillot D, Latrabe V, Thiébaut A, Herbrecht R, De Botton S, Pigneux A, Monchecourt F, Mahi L, Alfandari S, Couaillier JF: Computer tomography in pulmonary invasive aspergillosis in hematological patients with neutropenia: an useful tool for diagnosis and assessment of outcome in clinical trials. Eur J Radiol 2010; 74:e172-e175.
79. Nivoix Y, Velten M, Letscher-Bru V, Moghaddam A, Natarajan-Ame S, Fohrer C, Lioure B, Bilger K, Lutun P, Marcellin L, Launoy A, Freys G, Bergerat J, Herbrecht R: Factors associated with overall and attributable mortality in invasive aspergillosis. Clin Infect Dis 2008; 47: 1176-1184.
80. Garcia-Vidal C, Upton A, Kirby KA, Marr KA: Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. Clin Infect Dis 2008; 47: 1041-1050.
81. Wagner C, Graninger W, Presterl E, Joukhadar C: The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications. Pharmacology 2006; 78: 161-177. (Pubitemid 44948055)
82. Aoki T, Miyamoto T, Mori Y, Yoshimoto G, Yamauchi T, Kamezaki K, Takenaka K, Iwasaki H, Harada N, Nagafuji K, Shimono N, Teshima T, Akashi K: Successful allogeneic stem cell transplantation in two patients with acute myelogenous leukaemia and invasive aspergillosis by antifungal combination therapy. Mycoses 2011; 54:e255-e259.
83. Yamada R, Horikawa K, Ishihara S, Hoshino K, Kawaguchi T, Iyama K, Mitsuya H, Asou N: Successful treatment of Aspergillus liver abscesses in a patient with acute monoblastic leukemia using combination antifungal therapy including micafungin as a key drug. Int J Hematol 2010; 91: 711-715.
84. Wadi J, Al-Kawasmeh SI, Kamel MT, Al-Jayyousi BB: Disseminated invasive aspergillosis successfully treated with micafungin in a renal transplant recipient. Saudi J Kidney Dis Transpl 2010; 21: 914-918.
85. Denning DW, Marr KA, Lau WM, Facklam DP, Ratanatharathorn V, Becker C, Ullmann AJ, Seibel NL, Flynn PM, van Burik JA, Buell DN, Patterson TF: Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 2006; 53: 337-349. (Pubitemid 44524711)
86. Petraitis V, Petraitiene R, Groll AH, Bell A, Callender DP, Sein T, Schaufele RL, McMillian CL, Bacher J, Walsh TJ: Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother 1998; 42: 2898-2905. (Pubitemid 28501223)
87. Gadea I, Mensa J: Potential of anidulafungin in combined therapy (in Spanish). Enferm Infecc Microbiol Clin 2008; 26(suppl 14):51-55.
88. Steinbach WJ: Combination antifungal therapy for invasive aspergillosis: utilizing new targeting strategies. Curr Drug Targets Infect Disord 2005; 5: 203-210. (Pubitemid 41448367)
89. Singh N, Limaye AP, Forrest G, Safdar N, Munoz P, Pursell K, Houston S, Rosso F, Montoya JG, Patton P, del Busto R, Aguado JM, Fisher RA, Klintmalm GB, Miller R, Wagener MM, Lewis RE, Kontoyiannis DP, Husain S: Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 2006; 81: 320-326. (Pubitemid 43255714)
90. Lellek H, Waldenmaier D, Dahlke J, Ayuk FA, Wolschke C, Kröger N, Zander AR: Caspofungin plus posaconazole as salvage therapy of invasive fungal infections in immunocompromised patients. Mycoses 2011; 54(suppl 1):39-44.
91. Mihu CN, Kassis C, Ramos ER, Jiang Y, Hachem RY, Raad II: Does combination of lipid formulation of amphotericin B and echinocandins improve outcome of invasive aspergillosis in hematological malignancy patients? Cancer 2010; 116: 5290-5296.
92. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, Denning DW, Patterson TF, Maschmeyer G, Bille J, Dismukes WE, Herbrecht R, Hope WW, Kibbler CC, Kullberg BJ, Marr KA, Munoz P, Odds FC, Perfect JR, Restrepo A, Ruhnke M, Segal BH, Sobel JD, Sorrell TC, Viscoli C, Wingard JR, Zaoutis T, Bennett JE: Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-1821.
93. Segal BH, Herbrecht R, Stevens DA, Ostrosky-Zeichner L, Sobel J, Viscoli C, Walsh TJ, Maertens J, Patterson TF, Perfect JR, Dupont B, Wingard JR, Calandra T, Kauffman CA, Graybill JR, Baden LR, Pappas PG, Bennett JE, Kontoyiannis DP, Cordonnier C, Viviani MA, Bille J, Almyroudis NG, Wheat LJ, Graninger W, Bow EJ, Holland SM, Kullberg B, Dismukes WE, De Pauw BE: Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis 2008; 47: 674-683.